ZURICH (Reuters) – Roche’s Tecentric immunotherapy mixed with chemotherapy has not yet achieved a hoped-for overall survival target in first-line lung cancer treatment, the Swiss drugmaker said on Thursday.
FILE PHOTO: The logo of Swiss pharmaceutical company Roche is pictured on the company’s headquarters in Basel February 4, 2009. REUTERS/Christian Hartmann (SWITZERLAND)/File Photo
The Tecentriq combination with pemetrexed in non-small
cell lung cancer (NSCLC) did reduce the risk of the disease worsening or death, the Swiss drugmaker said.
The Basel-based company is still waiting for…